Rubius Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$511.1M
Industry:Biotech
Founded:N/A
Lead Investor(s):Flagship Ventures

Industry Ranking

Estimated Revenue & Financials

  • Rubius Therapeutics's estimated annual revenue is currently $13.2M per year.
  • Rubius Therapeutics received $100.0M in venture funding in March 2018.
  • Rubius Therapeutics's estimated revenue per employee is $61,854
  • Rubius Therapeutics's total funding is $511.1M.

Employee Data

  • Rubius Therapeutics has 213 Employees.
  • Rubius Therapeutics grew their employee count by -13% last year.
  • Rubius Therapeutics currently has 18 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM was designed to genetically engineer and culture Red Cell Therapeutics that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities - cellular shielding, potent cell-cell interaction and tolerance induction. We plan to file our first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. We are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond. The company, a 2017 Fierce 15 award winner, was founded in 2013, is based in Cambridge, MA and is currently expanding across the all functions within the organization. Having completed our an initial public offering (Nasdaq: RUBY), we are well capitalized to execute our vision and strategy. For more information, please visit us at www.rubiustx.com or follow us on Twitter.

keywords:Biotechnology,Healthcare,Pharmaceuticals

213

Number of Employees

$13.2M

Revenue (est)

18

Current Jobs

-13%

Employee Growth %

$511.1M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Greg WhiteheadChief Quality Officer
Irina KorolevaDirector, Translational Medicine
Laura HeveyExecutive Assistant To Chief Executive Officer
Pablo CagnoniChief Executive Officer
George O'SullivanHead Of Supply Chain
Elin WytrwalManager, Corporate Development & Strategy
Abigail BrachaChief Of Staff
Sivan ElloulDirector, oncology
Joanne ProtanoSenior Vice President, Finance & Operations
Aubrey TiernanPrincipal Engineer

Rubius Therapeutics News

09/03/2019 - Rubius Therapeutics Reports Second Quarter 2019 Financial ...

13, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically ...

09/03/2019 - Rubius Therapeutics to Participate in 17th Annual Morgan ...

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company ...

09/03/2019 - Why Everyone's Talking About Rubius Therapeutics, Inc ...

Today's big question for investors is, “what's going on with Rubius Therapeutics, Inc. (NASDAQ:RUBY) stock? Its price is jumping 0.51 points, ...

Rubius Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-12-10$25.0MAFlagship VenturesArticle
2017-06-22$120.0MUndisclosedArticle
2018-03-01$100.0MSecondArticle

Rubius Therapeutics Executive Hires

DateNameTitleReference
2017-01-05David EpsteinChairmanArticle
2017-08-09David EpsteinExecutive ChairmanArticle
2017-09-28Chris Carpenterchief medical officerArticle
2017-12-15Andrew OhCFOArticle
2018-02-02Francis CussChirArticle
2018-02-21Spencer FiskSenior Vice President, ManufacturinArticle
2018-06-07Pablo CagnoniChief Executive OfficerArticle
2019-03-26Greg WhiteheadSenior Vice President and Chief Quality OfficerArticle